TopFunds

Novo Nordisk A/S

NYSE: NVO

Stock price

50.32 USD

(+Infinity%) NaN day

medicineDrug Manufacturers - GeneralInvestable Universe

Financial Performance

Share

5Y price score: 18

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 114.9%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    35.1

    52-week range

    71.8

    50.32

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    2.1 %

    Dividend Yield TTM

    3.5 %

    Market cap $

    $ 223,611

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    12

    Price / Book TTM

    7.2

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    6.8

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    (20.3) %

    26.5 %

    114.8 %

    Free cash flow per share growth

    (58.2) %

    2.1 %

    5.4 %

    Earnings per share growth

    1.8 %

    155.6 %

    240.7 %

    Founded: 1,923

    Employees: 69,260

    Business Summary:Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    2026 Q1 (May 6, 2026)

    1) Strategy & Leadership
    - Novo Nordisk is focused on enhancing competitiveness and advancing its pipeline while making strategic investments for growth. - The company is currently treating over 45 million people with obesity and diabetes, with more than 4 million using obesity treatments. - The launch of the Wegovy pill and high-dose Wegovy (7.2 mg) is a key part of their strategy, with significant uptake noted since their introduction. - The company aims to drive growth through innovation, partnerships, and resource allocation, including a collaboration with OpenAI.

    2) Financial & Segment Results
    - Reported sales increased by 32% YoY to DKK 96.8 billion, but adjusted sales decreased by 4% due to lower realized prices, despite GLP-1 volume growth. - U.S. operations saw an 11% decline in sales, while international operations grew by 6%. Obesity care sales increased by 22%, with international operations growing by 44%. - Adjusted gross margin decreased to 80.6% from 83.5% in 2025, and adjusted operating profit decreased by 6% at CER. - The company returned nearly DKK 38 billion to shareholders through dividends and share buybacks.

    3) Operational & Product Plans
    - The Wegovy pill has reached over 1 million users since its launch, with 1.3 million total TRxs in Q1. - The high-dose Wegovy has been launched nationwide, with a significant mean weight loss reported in clinical trials. - Novo Nordisk has initiated multiple clinical trials and received several regulatory approvals, including for CagriSema and Etavopivat. - The company plans to launch Wegovy in select international markets in H2 2026.

    4) Guidance & Outlook
    - Adjusted sales growth for 2026 is now expected to be between -4% and -12% at CER, reflecting increased expectations for GLP-1 product sales. - The company is on track to deliver DKK 8 billion in savings from a company-wide transformation, which will be reinvested into growth opportunities. - The outlook considers current prescription trends, competition, and potential impacts from Medicaid coverage changes.

    5) Problems / Headwinds
    - The company faces challenges from lower realized prices and competition in the U.S. market, particularly for its GLP-1 products. - There are concerns about the impact of generics on pricing and market share, especially in Canada and other markets. - The company is managing inventory levels and pricing dynamics carefully to mitigate these challenges.

    Bottom line: Novo Nordisk is navigating a complex landscape with strong product launches and a robust pipeline, but faces headwinds from pricing pressures and competition. The strategic focus on innovation and market expansion positions the company for potential growth, making it an interesting prospect for shareholders.

    Novo Nordisk A/S — Financial Overview, Stock Price, Market Cap

    Novo Nordisk A/S is a company. Founded in 1923. As of July 20, 2026, the company's market capitalization is $223611092074 with a current stock price of $50.32.